Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
- 14 July 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (39) , 4141-4156
Abstract
Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and central/truncal obesity), and shared metabolic and functional abnormalities lead to damage throughout these organs via overlapping pathophysiological pathways. The COVID-19 pandemic has further complicated the management of cardiometabolic diseases. Obesity, T2DM, CKD, and liver disease are associated with increased risk of poor outcomes of COVID-19 infection, and conversely, COVID-19 can lead to worsening of pre-existing ASCVD. The high rates of these comorbidities highlight the need to improve recognition and treatment of ASCVD in patients with obesity, insulin resistance or T2DM, chronic liver diseases, and CKD and equally, to improve recognition and treatment of these diseases in patients with ASCVD. Strategies to prevent and manage cardiometabolic diseases include lifestyle modification, pharmacotherapy, and surgery. There is a need for more programmes at the societal level to encourage a healthy diet and physical activity. Many pharmacotherapies offer mechanism-based approaches that can target multiple pathophysiological pathways across diseases. These include sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, selective mineralocorticoid receptor antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist. Non-surgical and surgical weight loss strategies can improve cardiometabolic disorders in individuals living with obesity. New biomarkers under investigation may help in the early identification of individuals at risk and reveal new treatment targets.Keywords
This publication has 174 references indexed in Scilit:
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosisNature Reviews Gastroenterology & Hepatology, 2013
- Weight Loss Interventions in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Prehypertension, Obesity, and Risk of Kidney Disease: 20-Year Follow-up of the HUNT I Study in NorwayAmerican Journal of Kidney Diseases, 2009
- Effects of Structured Versus Usual Care on Renal Endpoint in Type 2 Diabetes: The SURE StudyDiabetes Care, 2009
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in MiceDiabetes, 2009
- Association between obesity and kidney disease: A systematic review and meta-analysisKidney International, 2008
- Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years OldNew England Journal of Medicine, 2006
- Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the HeartHeart, 2006
- Waist/Height Ratio as a Better Predictor of Type 2 Diabetes Compared to Body Mass Index in Tehranian Adult Men - a 3.6-Year Prospective StudyExperimental and Clinical Endocrinology & Diabetes, 2006
- Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful ReperfusionCirculation, 2004